Sign in
CompletedPhase 1

Oxytocin, Stress, Craving, Opioid Use Disorder

Key facts

Who runs it
Brown University
Where
Providence, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1
People taking part
20 people enrolled
Started
6 Jan 2020
Ended
23 Dec 2023
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • intranasal oxytocin, 40 IU, twice a day for 7 days
Record updated
25 May 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Male or female (50%), 18 to 70 (inclusive) years of age
  • Currently meets DSM-5 criteria for OUD
  • Currently on a stable dose of buprenorphine/naloxone or methadone for at least 3 months
  • In good health as confirmed by medical history, physical examination and blood work (Liver function within 5x the Upper normal limits (AST/ALT) and renal function within 2x the Lower Normal Limit (bilirubin, creatine clearance)
  • Willing to take medication and adhere to the study procedures;- Understand informed consent and questionnaires in English at an 8th grade level
  • Clinical Opiate Withdrawal Scale (COWS) = 0 at study screening and prior laboratory sessions

Who cannot take part

  • Current use of medications that may interact with study medications
  • Clinically significant electrolyte abnormalities, current rhinitis or use of vasoconstricting medications or prostaglandins
  • Current substance disorder other than marijuana, nicotine and caffeine as assessed by self-report and urine toxicology screen at baseline
  • History of hypersensitivity to study medications
  • Women who are breastfeeding, test positive for pregnancy or are unwilling to use medically-approved birth control
  • Suicide attempts in the last three months

Where in United States

  • Brown UniversityProvidence, United States

About the trial

What the trial wants to find out

Although stress has long been linked to substance use, craving and relapse, there are no available medications that target stress-induced substance use disorder (SUD). In particular, with the rise in opioid use, there is still a crucial need for developing effective pharmacological treatments that target and integrate the complexity of this disease. The long term goal of this project is to identify the key neuroendocrine pathways that are responsible for stress-induced craving in individuals with opioid use disorder (OUD) in order to better understand how they can be effectively treated.

The 2 groups in the trial

  • Oxytocin first, then placeboTreatment being tested

    Oxytocin was administered as 40 IU/0.12 mL nasal spray in each nostril once in the morning and once in the afternoon for 7 days. After a 2 day washout period, Placebo was administered as nasal spray in each nostril once in the morning and once in the afternoon for 7 days.

    Treatment: intranasal oxytocin, 40 IU, twice a day for 7 days

  • Matching placebo, then oxytocinPlacebo, for comparison

    Placebo was administered as nasal spray in each nostril once in the morning and once in the afternoon for 7 days. After a 2 day washout period, oxytocin was administered as 40 IU/0.12 mL nasal spray in each nostril once in the morning and once in the afternoon for 7 days.

    Treatment: intranasal oxytocin, 40 IU, twice a day for 7 days

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Oxytocin to Reduce Stress-induced Craving in Individuals With Opioid Use Disorder
Record updated
25 May 2025